WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, an imatinib-treated patient with CML who was intradermally administered a WT1 peptide vaccine elicited WT1-specific immune responses and had a resultant reduction in persistent residual disease with the co-administration of imatinib.